NEW YORK – Canadian precision medicine lab services provider CellCarta has acquired Belgian genomic testing solutions firm Biogazelle. Financial terms of the acquisition were not disclosed.
Biogazelle develops and deploys digital PCR, qPCR, and RNA-seq assays for pharmaceutical and biotech industry clients, while CellCarta provides specialized precision medicine laboratory services to the biopharmaceutical industry with facilities in Canada, the US, Belgium, Australia, and China.
Biogazelle will continue to offer its current genomic services and will also become CellCarta's Center of Excellence for the development of complex genomic biomarker assays, according to a statement.
The acquisition allows CellCarta to expand its offering to clients in fields with high demand in genomic analysis, such as immuno-oncology and cell and gene therapy, the firm said. It is also intended to solidify CellCarta's leadership position in genomic services "with a unique combination of assay development and global clinical trial sample analysis capabilities" that encompass a range of genomic technologies.
"Biogazelle's exceptional genomics expertise will enable CellCarta to further support its clients' therapeutic development strategies, offering them key solutions to address their clinical challenges and move their immunology and other programs forward," Martin LeBlanc, CEO of CellCarta, said in a statement.